---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-23-000240"
form_type: "8-K"
ticker: "UTMD"
cik: "0000706698"
company_name: "UTAH MEDICAL PRODUCTS INC"
filed_at: "2023-01-31T23:59:59+00:00"
generated_at: "2026-06-20T05:56:56.082477+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# UTMD Q4 EPS $1.253, up 11% YoY; FY22 EPS $4.522, up 12%; dividend raised to $0.295

## Summary
- Q4 revenue $13.6M (+5.1% YoY); FY22 revenue $52.3M (+6.6% YoY); constant currency sales up ~10% for the year.
- Gross margin declined to 61.3% (Q4) and 61.6% (FY22) from 62.8%/63.0% on higher manufacturing costs and raw materials.
- FY22 operating income $19.8M (+4.8%) despite $670K in litigation expenses vs $22K in 2021; cash & investments rose to $75.1M.
- Repurchased 30,105 shares at $82.88 in Q2 2022; quarterly dividend increased to $0.295/share effective Jan 2023 payment.
- Outstanding shares 3.63M at year-end; diluted shares 3.64M; no debt on balance sheet.

## SEC filing metadata
- accession: 0001096906-23-000240
- form_type: 8-K
- ticker: UTMD
- cik: 0000706698
- company_name: UTAH MEDICAL PRODUCTS INC
- filed_at: 2023-01-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01, 99.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/706698/000109690623000240/0001096906-23-000240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/706698/000109690623000240/utmd-20230131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-23-000240
- JSON: https://secwatch.observer/filing/0001096906-23-000240.json
- Plain text: https://secwatch.observer/filing/0001096906-23-000240.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.